Protalix BioTherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M | -$20.5M |
| Cost of revenue | $27.0M | $24.3M | $23.0M | $19.6M | $16.3M |
| Cash from operations | -$12.0M | $8.7M | -$1.3M | -$25.0M | -$10.3M |
| Capital expenditure | $1.6M | $1.3M | $1.1M | $628,000 | $1.5M |
| Free cash flow | -$13.6M | $7.4M | -$2.5M | -$25.6M | -$11.7M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M |
Shares outstanding 80.6M · Free float 85.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.